Skip to main content
. 2020 Nov 28;80(18):1901–1928. doi: 10.1007/s40265-020-01422-9

Fig. 4.

Fig. 4

Adaptive immune cell counts in patients with RMS receiving cladribine 3.5 mg/kg or placebo—B (CD19+) cells [64]. LLN lower limit of normal, Q1–Q3 interquartile range, RMS relapsing multiple sclerosis. Pooled data from CLARITY, CLARITY EXT, and PREMIERE. Visits with a sample size ≥ 30 are displayed. Adapted with permission from Comi et al. [64]